Ozmosi | Olpadronic acid Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Olpadronic acid

Pronounced as: ol-pa-DRON-ik AS-id

Alternative Names: olpadronic acid
Clinical Status: Active
Latest Update: None
Latest Update Note: None

Product Description

Mechanisms of Action: Osteoclast Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gador S.A.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Chronic Pain|Low Back Pain

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2015-004269-96

2015-004269-96

P2

Active, not recruiting

Low Back Pain|Chronic Pain

2017-08-24

2022-03-13

Treatments

Recent News Events

Date

Type

Title